Drug Trial Radar · NCT00001993
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- G D SearleIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the preliminary efficacy and tolerability of combining a selected dose of SC-48334 with low-dose AZT in the treatment of symptomatic HIV+ patients with 200 to 500 CD4+ cells/mm3. The secondary objective is to determine the pharmacokinetics and bioavailability of both SC-48334 and AZT, when administered together, in symptomatic HIV+ patients with 200 - 500 CD4+ cells/mm3.
Conditions
- HIV Infections
Interventions
ButyldeoxynojirimycinDrug
ZidovudineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Univ of Miami School of Medicine
Miami, Florida
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois
Infectious Diseases Research Clinic / Indiana Univ Hosp
Indianapolis, Indiana
Ohio State Univ Hosp Clinic
Columbus, Ohio
Julio Arroyo
West Columbia, South Carolina
Univ of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.